Cell therapy is no longer a future concern for self-funded employers. It’s an active and rapidly evolving category of stop loss risk. Early CAR-T claims were viewed as rare, but today the risk is broader. Access is improving, indications are expanding and treatment timelines don’t always fit neatly inside a 12-month policy year.
Here are five practical conversations brokers should be having with their self-funded clients:
1. Stop treating CAR-T as a “one-off” scenario
CAR-T therapy is now an established treatment for certain blood cancers. The base cost typically exceeds $750,000 and total costs often reach $1-3 million once hospital care and complications are included. For employers with higher-risk oncology populations, this is no longer a remote possibility, it’s a realistic exposure.
The conversation: Help clients understand that this risk should be assumed in certain populations—especially for small and mid-sized groups where one claim can impact the plan’s financial results.
2. Look beyond the drug price
The therapy cost gets the headlines, but the complications often drive the real volatility. Immune-related complications can add $100,000 to $1 million or more in additional ICU and inpatient costs. In some cases, those complications cost as much as the therapy itself.
The conversation: When modeling risk or reviewing renewals, focus on total episode cost, not just the price of the drug.
3. Pay attention to timing
Cell therapy claims don’t always fit neatly inside a single policy year. Between preparation, infusion and managing side effects, treatment can stretch over several months and sometimes across two policy years.
The conversation: Review contract language carefully. Run-in, run-out and renewal timing matter more in this environment. Make sure clients understand how multi-year claims can impact renewal negotiations.
4. Watch utilization, not just price trends
One of the biggest shifts isn’t price reduction, it’s improved access. Manufacturing timelines for CAR-T have dropped dramatically. Faster turnaround means more eligible patients can actually receive treatment. As approvals expand and access improves, frequency may increase, even if pricing stays the same.
The conversation: Help clients think about how many members could qualify, not just how much a single case might cost.
5. Prepare for expansion within cell therapy
Today, most CAR-T exposure is concentrated in certain blood cancers, such as lymphomas and leukemias. While these claims are high severity, the eligible population remains relatively narrow, for now. Research is actively exploring CAR-T and other cell therapies for solid tumors, including high-prevalence cancers such as pancreatic cancer. Solid tumors affect significantly larger populations than hematologic malignancies. Pricing for these therapies is expected to remain at or above current CAR-T levels—which already exceed $750,000 for the therapy alone, with total episode costs often reaching $1-3 million or more.
The conversation: Brokers should begin preparing clients for the possibility that cell therapy exposure could expand beyond today’s narrower oncology footprint. What feels like a contained risk today could become a more frequent exposure within the next 5-10 years.
The bottom line
Cell therapy is shifting from isolated shock claims to an emerging category of risk. The most important question is no longer, “How expensive is one therapy?” It is, “how often could this happen in my population and how prepared are we?” Brokers who lead these conversations now can help clients avoid surprises later. In a rapidly evolving landscape, proactive strategy is more valuable than reactive response.
